AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
I-Mab shares rise 5.65% premarket after Everest Medicines' positive H1 2025 earnings report.
ByAinvest
Friday, Aug 29, 2025 7:08 am ET1min read
I-Mab rose 5.65% in premarket trading, with Everest Medicines, a biopharmaceutical company, announcing its interim results for the first half of 2025. The company reported accelerating its transformation into a leading global biopharmaceutical company by deepening its 'dual-engine' strategy, which includes building a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet